{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:21:52Z","timestamp":1793830912582,"version":"4.6.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1245\/s10434-025-17432-4","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T18:32:10Z","timestamp":1747506730000},"page":"5616-5623","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intraperitoneal Intraoperative Chemotherapy in Advanced Ovarian Cancer: Rethinking the Future Beyond Complete Macroscopic Resection"],"prefix":"10.1245","volume":"32","author":[{"given":"Pedro Antonio","family":"Cascales-Campos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Lacueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Carbonell-Morote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alida","family":"Gonzalez-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Alcaraz-Solano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iban","family":"Caravaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Aranaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"G\u00f3mez-Due\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gil-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Arjona-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Ramia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"17432_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ygyno.2010.05.025","volume":"118","author":"RE Bristow","year":"2010","unstructured":"Bristow RE, Palis BE, Chi DS, Cliby WA. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol. 2010;118:262\u20137.","journal-title":"Gynecol Oncol."},{"key":"17432_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/IGC.0b013e31819915cb","volume":"19","author":"C Marth","year":"2009","unstructured":"Marth C, Hieble S, Oberainger W, Winter R, Leodolter S, Sevelda P. Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association for Gynecologic. Int J Gynecol Cancer. 2009;19:94\u201310.","journal-title":"Int J Gynecol Cancer."},{"key":"17432_CR3","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194\u2013200.","journal-title":"J Clin Oncol."},{"key":"17432_CR4","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","volume":"34","author":"AA Wright","year":"2016","unstructured":"Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34:3460\u201373.","journal-title":"J Clin Oncol."},{"key":"17432_CR5","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473\u201383.","journal-title":"N Engl J Med."},{"issue":"26","key":"17432_CR6","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799S","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1103799S.","journal-title":"N Engl J Med."},{"key":"17432_CR7","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. prima\/engot-ov26\/gog-3012 investigators. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391\u2013402.","journal-title":"N Engl J Med."},{"key":"17432_CR8","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, et al. PAOLA-1 Investigators. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416\u201328.","journal-title":"N Engl J Med."},{"key":"17432_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","volume":"7","author":"D Cort\u00e9s-Guiral","year":"2021","unstructured":"Cort\u00e9s-Guiral D, H\u00fcbner M, Alyami M, Bhatt A, Ceelen W, Glehen O, et al. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers. 2021;7:91.","journal-title":"Nat Rev Dis Primers."},{"key":"17432_CR10","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(21)01061-8","volume":"397","author":"LM Hurwitz","year":"2021","unstructured":"Hurwitz LM, Pinsky PF, Trabert B. General population screening for ovarian cancer. Lancet. 2021;397:2128\u201330.","journal-title":"Lancet."},{"key":"17432_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin."},{"key":"17432_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1136\/ijgc-2022-003985","volume":"33","author":"MA Angeles","year":"2023","unstructured":"Angeles MA, Spagnolo E, Cabarrou B, P\u00e9rez-Benavente A, Gil Moreno A, Guyon F, et al. Impact of pattern of recurrence on post-relapse survival according to surgical timing in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2023;33:50\u20136.","journal-title":"Int J Gynecol Cancer."},{"key":"17432_CR13","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950\u20135.","journal-title":"N Engl J Med."},{"key":"17432_CR14","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001\u20137.","journal-title":"J Clin Oncol."},{"key":"17432_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34\u201343.","journal-title":"N Engl J Med."},{"key":"17432_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","volume":"130","author":"LM Landrum","year":"2013","unstructured":"Landrum LM, Java J, Mathews CA, Lanneau GS Jr, Copeland LJ, Armstrong DK, Walker JL. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;130:12\u20138.","journal-title":"Gynecol Oncol."},{"key":"17432_CR17","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230\u201340.","journal-title":"N Engl J Med."},{"key":"17432_CR18","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","volume":"24","author":"SL Aronson","year":"2023","unstructured":"Aronson SL, Lopez-Yurda M, Koole SN, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol. 2023;24:1109\u201318.","journal-title":"Lancet Oncol."},{"key":"17432_CR19","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","volume":"29","author":"CCP Antonio","year":"2022","unstructured":"Antonio CCP, Alida GG, Elena GG, Roc\u00edo GS, Jer\u00f3nimo MG, Luis ARJ, et al. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial. Ann Surg Oncol. 2022;29:2617\u201325.","journal-title":"Ann Surg Oncol."},{"key":"17432_CR20","doi-asserted-by":"crossref","unstructured":"Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, Park SY; HIPEC for Ovarian Cancer Collaborators. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg. 2022;157:374\u201383","DOI":"10.1001\/jamasurg.2022.0143"},{"key":"17432_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100586","volume":"7","author":"P Filis","year":"2022","unstructured":"Filis P, Mauri D, Markozannes G, Tolia M, Filis N, Tsilidis K. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO Open. 2022;7:100586.","journal-title":"ESMO Open."},{"key":"17432_CR22","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamasurg.2023.3944","volume":"158","author":"JY Lee","year":"2023","unstructured":"Lee JY, Lee YJ, Son JH, Kim S, Choi MC, Suh DH, et al. Hyperthermic intraperitoneal chemotherapy after interval cytoreductive surgery for patients with advanced-stage ovarian cancer who had received neoadjuvant chemotherapy. JAMA Surg. 2023;158:1133\u201340.","journal-title":"JAMA Surg."},{"key":"17432_CR23","doi-asserted-by":"publisher","first-page":"896","DOI":"10.6004\/jnccn.2019.0039","volume":"17","author":"DK Armstrong","year":"2019","unstructured":"Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, et al. NCCN guidelines insights: Ovarian cancer, version 1.2019. J Natl Compr Canc Netw. 2019;17:896\u2013909.","journal-title":"J Natl Compr Canc Netw"},{"key":"17432_CR24","doi-asserted-by":"crossref","unstructured":"Classe JM, Meeus P, Hudry D, Wernert R, Quenet F, Marchal F, et al; UNICANCER\/CHIPOR Investigators. Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2024:S1470-2045(24)00531-X.","DOI":"10.1016\/S1470-2045(24)00531-X"},{"key":"17432_CR25","unstructured":"Doyle DJ, Hendrix JM, Garmon EH. American Society of Anesthesiologists Classification. 2023 Aug 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024"},{"key":"17432_CR26","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245\u201351.","journal-title":"J Clin Epidemiol."},{"key":"17432_CR27","doi-asserted-by":"crossref","unstructured":"Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1\u20135.","DOI":"10.1016\/j.ijgo.2013.10.001"},{"key":"17432_CR28","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.ejso.2021.05.019","volume":"47","author":"M Lomnytska","year":"2021","unstructured":"Lomnytska M, Karlsson E, Jonsdottir B, Lejon AM, St\u00e5lberg K, Poromaa IS, et al. Peritoneal cancer index predicts severe complications after ovarian cancer surgery. Eur J Surg Oncol. 2021;47:2915\u201324.","journal-title":"Eur J Surg Oncol."},{"key":"17432_CR29","doi-asserted-by":"crossref","unstructured":"Llueca A, Escrig J; MUAPOS Working Group (Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery). Prognostic value of peritoneal cancer index in primary advanced ovarian cancer. Eur J Surg Oncol. 2018;44:163\u20139","DOI":"10.1016\/j.ejso.2017.11.003"},{"key":"17432_CR30","doi-asserted-by":"crossref","unstructured":"Padilla-Iserte P, Iv\u00e1\u00f1ez M, Muruzabal JC, Navarro R, D\u00edaz-Feijoo B, Iacoponi S, et al; SEGO Spain-GOG Group. Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role. Eur J Surg Oncol. 2024;50:108263","DOI":"10.1016\/j.ejso.2024.108263"},{"key":"17432_CR31","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/bjc.2013.70","volume":"108","author":"JL Lesnock","year":"2013","unstructured":"Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group study. Br J Cancer. 2013;108:1231\u20137.","journal-title":"Br J Cancer."},{"key":"17432_CR32","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/ijc.34124","volume":"151","author":"SN Koole","year":"2022","unstructured":"Koole SN, Schouten PC, Hauke J, Kluin RJC, Nederlof P, Richters LK, et al. Effect of HIPEC according to HRD\/BRCAwt genomic profile in stage III ovarian cancer: results from the phase III OVHIPEC trial. Int J Cancer. 2022;151:1394\u2013404.","journal-title":"Int J Cancer."},{"key":"17432_CR33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.suronc.2016.05.010","volume":"25","author":"P Cascales-Campos","year":"2016","unstructured":"Cascales-Campos P, L\u00f3pez-L\u00f3pez V, Gil J, Ar\u00e9valo-P\u00e9rez J, Nieto A, Barcel\u00f3 F, et al. Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C\/IV ovarian cancer is there any difference? Surg Oncol. 2016;25:164\u201370.","journal-title":"Surg Oncol."},{"key":"17432_CR34","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s12094-019-02065-3","volume":"21","author":"I Manzanedo","year":"2019","unstructured":"Manzanedo I, Pereira F, Serrano \u00c1, P\u00e9rez-Viejo E, Mart\u00ednez-Torres B, Carri\u00f3n L, Calzas J. The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study. Clin Transl Oncol. 2019;21:1357\u201363.","journal-title":"Clin Transl Oncol."},{"key":"17432_CR35","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.3390\/cancers15133481","volume":"15","author":"A Gonz\u00e1lez Gil","year":"2023","unstructured":"Gonz\u00e1lez Gil A, CerezuelaFern\u00e1ndez-de Palencia \u00c1, G\u00f3mez Ruiz \u00c1J, Gil G\u00f3mez E, L\u00f3pez Hern\u00e1ndez F, Nieto Ruiz A, et al. HIPEC in ovarian cancer is the future\u2026and always will be? Results from a Spanish multicentric survey. Cancers Basel. 2023;15:3481.","journal-title":"Cancers Basel."},{"key":"17432_CR36","doi-asserted-by":"publisher","first-page":"100945","DOI":"10.1016\/j.gore.2022.100945","volume":"39","author":"RM van Stein","year":"2022","unstructured":"van Stein RM, Lok CAR, Aalbers AGJ, de Ignace HJT, Hingh API, Houwink HJ, et al. Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus. Gynecol Oncol Rep. 2022;39:100945.","journal-title":"Gynecol Oncol Rep"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17432-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17432-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17432-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T13:59:58Z","timestamp":1751464798000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17432-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["17432"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17432-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors have any conflicts of interest or commercial interest in the subject of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}